Bristol Myers Squibb (BMS) drug Abecma was the first FDA-approved CAR T-cell therapy for multiple myeloma, but like other drugs in its class, the treatment’s serious side effect risks limit its use to ...
Roughly two years after securing a former Novartis facility in Illinois to support its CAR-T cancer treatments Breyanzi and Abecma, Bristol Myers Squibb is rethinking its operations at the site. BMS ...
Bristol Myers Squibb (BMS) and Immatics will develop up to seven cancer cell therapies by launching a new partnership and expanding a three-year-old collaboration inked by BMS predecessor Celgene, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback